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Original ArticleAtopic Eczema in Adulthood and Risk of
Depression and Anxiety: A Population-Based
Cohort StudyYochai Schonmann, MD, MSca,b,c,*, Kathryn E. Mansfield, MBBS, BSc, MRes, PhDa,*,
Joseph F. Hayes, MBChB, MSc, PhDd,e, Katrina Abuabara, MD, MsCE, MAf, Amanda Roberts, BScg,
Liam Smeeth, MBChB, FRCGP, FFPH, FRCP, MSc, PhD, FMedScia, and Sinéad M. Langan, FRCP, MSc, PhDa,h,i London
and Nottingham, United Kingdom; Petah Tikva and Tel-Aviv, Israel; and San Francisco, CalifWhat is already known about this topic? Atopic eczema is a common debilitating skin condition. An association be-
tween atopic eczema and common mental disorders is well documented, but its nature and temporal direction remain
unclear.
What does this article add to our knowledge? Individuals affected with atopic eczema are more likely to develop new
depression (14% increased incidence) and anxiety (17% increased incidence). The observed dose-response relationship
between atopic eczema severity and depression supports a causal mechanism for the association.
How does this study impact current management guidelines? Recent atopic eczema guidelines comment briefly on
the influence of psychological and emotional factors on the clinical course of atopic eczema. Our findings suggest that
depression and anxiety should be addressed explicitly in updated guidelines.BACKGROUND: Atopic eczema is a common and debilitating
condition associated with depression and anxiety, but the nature
of this association remains unclear.
OBJECTIVE: To explore the temporal relationship between
atopic eczema and new depression/anxiety.
METHODS: This matched cohort study used routinely collected
data from the UK Clinical Practice Research Datalink, linked to
hospital admissions data. We identified adults with atopic
eczema (1998-2016) using a validated algorithm, and up to 5
individuals without atopic eczema matched on date of diagnosis,
age, sex, and general practice. We estimated the hazard ratio
(HR) for new depression/anxiety using stratified Cox regression
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248Deprivation, glucocorticoid treatment, obesity, smoking, and
harmful alcohol use.
RESULTS: We identified 526,808 adults with atopic eczema who
were matched to 2,569,030 without. Atopic eczema was associated
with increased incidence of new depression (HR, 1.14; 99% CI,
1.12-1.16) and anxiety (HR, 1.17; 99% CI, 1.14-1.19). We
observed a stronger effect of atopic eczema on depression with
increasing atopic eczema severity (HR [99% CI] compared with
no atopic eczema: mild, 1.10 [1.08-1.13]; moderate, 1.19 [1.15-
1.23]; and severe, 1.26 [1.17-1.37]). A dose-response association,
however, was less apparent for new anxiety diagnosis (HR [99%
CI] compared with no atopic eczema: mild, 1.14 [1.11-1.18];
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HR- Hazard ratioCONCLUSIONS: Adults with atopic eczema are more likely to
develop new depression and anxiety. For depression, we
observed a dose-response relationship with atopic eczema
severity.  2019 The Authors. Published by Elsevier Inc. on
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INTRODUCTION
Atopic eczema (eczema, atopic dermatitis) is a chronic re-
lapsing inflammatory skin disease. It can cause intense itching
and discomfort. Itch and disfiguring lesions result in sleeplessness
and social embarrassment, impairing the quality of life of both
sufferers and their families.1,2 Atopic eczema is common (20% of
children and up to 10% of adults in developed countries) and is a
major cause of years lost because of disability.2-4 Emerging evi-
dence suggests that biologic agents, an effective treatment mo-
dality for severe atopic eczema,2,5,6 may also reduce symptoms of
depression and anxiety among people with atopic eczema.7
Mental health disorders are one of the leading causes of
disability worldwide,8 with depression and anxiety together ac-
counting for more than half of that burden.9 Depression, man-
ifesting as loss of interest and enjoyment in ordinary things and
experiences, affects approximately 4.4% of the global population;
anxiety disorders, characterized by excessive fear, anxiousness, or
avoidance of perceived threats, affect approximately 3.6%.10
Both depression and anxiety are associated with increased
morbidity and mortality.11-15 Atopic eczema has been shown to
be associated with common mental disorders (depression and
anxiety) and suicidality in cross-sectional studies that have
frequently relied on self-reported exposures and outcomes.16-25
Individuals with atopic eczema may be more likely to experi-
ence depression and anxiety through the effects of itch and
discomfort, disfigurement, and perceived social-stigmatization26-
28; in addition, poor sleep related to atopic eczema may increase
the risk of mental illness.29,30 Inflammatory mediators in atopic
eczema could also contribute to the development of depres-
sion.22,31 However, those with depression and anxiety could also
be more likely to consult for a physical condition such as atopic
eczema. Because longitudinal evidence is scarce and conflicting,
the temporality of any association between atopic eczema and
depression and anxiety, and whether the relationship changes
with increasing atopic eczema severity, remains unclear.32-34
Insight into the temporal relationship between atopic eczema
and depression/anxiety could guide the clinical approach to this
vulnerable group with visible and potentially stigmatizing skin
disease. Atopic eczema is common, so if people with atopic
eczema are indeed at increased risk of new-onset depression oranxiety, then this would suggest: (1) a major population impact;
(2) a potential role for targeted mental health screening for in-
dividuals with atopic eczema; and (3) the possibility of mental
health modification through improved atopic eczema control (eg,
using new biologic agents). Therefore, we aimed to investigate
the association between atopic eczema and newly diagnosed
depression and anxiety, and whether any association increased
with increasing atopic eczema severity, through a longitudinal
analysis of UK primary care electronic health record data.
METHODS
Study design and setting
We conducted a cohort study, using routinely collected primary
care electronic health record data from practices contributing to the
UK Clinical Practice Research Datalink (CPRD) and linked hospital
admissions data from the Hospital Episode Statistics (HES) database.
The CPRD covers approximately 7% of theUK population, is broadly
representative of the general population, and includes demographic
information, diagnoses, prescriptions, and secondary care referrals.35
Diagnoses are recorded in the CPRD using Read codes,36 and have
been demonstrated to be valid.37,38 The CPRD ensures high-quality
data through algorithmic analysis of gaps in data entry and deaths
recorded by each practice.35 HES includes data on all the National
Health Serviceefunded inpatient hospital stays in England since
1997, including diagnoses recorded using the International
Classification of Diseases, Tenth Revision coding system.39 Linkage to
HES data is available in approximately 80% of English CPRD prac-
tices. The study period was from January 2,1998, to March 31, 2016.
Ethical approval
The study protocol was approved by the Independent Scientific
Advisory Committee (ISAC) for the CPRD (ISAC protocol no.
16_100RA) and the London School of Hygiene and Tropical
Medicine (Reference: 15460). Informed consent was not required,
because the study used anonymized data.
Study population
Individuals with atopic eczema and disease sever-
ity. Atopic eczema diagnosis was based on a validated algorithm
(positive predictive value of 82%) requiring a record of at least 1
diagnostic code for atopic eczema and at least 2 records for atopic
eczema therapy.40 Systemic glucocorticoids were not included in the
validated algorithm to identify atopic eczema, and their use is
generally discouraged41 (see this article’s “Codes and treatments used
in algorithm definition of atopic eczema” section in the Online
Repository at www.jaci-inpractice.org). Other inclusion criteria
were: adults 18 years and older; eligible for HES linkage; registered
with a CPRD practice meeting CPRD patient- and practice-level
quality control standards; and contribution of valid follow-up time
during the study period (January 2, 1998, to March 31, 2016).
To capture the progressive nature of atopic eczema and to avoid
immortal-time bias, atopic eczema severity was modeled as a time-
updated variable.42 We categorized severity into 3, mutually exclu-
sive, progressive categories (mild, moderate, and severe) according to
recorded atopic eczema therapy.5,43,44 By default, all individuals
with atopic eczema were classified as having mild disease. They could
be recategorized as having (1) moderate atopic eczema if potent
topical steroids or calcineurin inhibitors were prescribed or (2) severe
atopic eczema, if there was a record for a referral to a dermatologist,
or a record for systemic treatment. Individuals with moderate/severe
disease kept their severity category until the end of follow-up and
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“Codes and treatments used in algorithm definition of atopic
eczema” section).
Comparison group of individuals without atopic
eczema. Each atopic eczemaeexposed individual was matched
(without replacement) with up to 5 individuals without atopic
eczema on sex, age, general practice, and calendar time. Unexposed
individuals had no record of a diagnostic code for atopic eczema (in
CPRD or HES) but were required to have at least 1 year of follow-
up in CPRD as well as meet all other inclusion criteria. To minimize
selection bias due to the exclusion of unmatched individuals and
closely adjust for its effects, age was matched in 15-year strata and
used as the underlying time scale for all analysis. To avoid mis-
classifying unexposed person-time, individuals could contribute
unexposed person-time until the date of their first record of a
diagnostic code for atopic eczema, regardless of later therapies pre-
scribed (see Figure E1 in this article’s Online Repository at www.
jaci-inpractice.org).
Outcomes
We considered depression and anxiety as separate outcomes, with
onset defined as the date of the first recorded diagnosis in either
CPRD or HES (any inpatient hospital diagnosis). Codes for the
depression outcome were those compatible with unipolar depres-
sion,45 and for the anxiety outcome, included those consistent with
generalized anxiety and panic disorders. We considered broader
definitions of depression and anxiety in prespecified sensitivity an-
alyses (see this article’s “Code lists for the outcomes (depression and
anxiety)” section in the Online Repository at www.jaci-inpractice.
org).
Defining follow-up
Individuals entered the cohort at the latest of: practice registration
date plus 12 months; the date their practice met CPRD quality
control standards; the date an individual met our atopic eczema
diagnosis definition; or the start of the study (January 2, 1998).
Individuals without atopic eczema entered the cohort on the same
day as their matched atopic eczemaeexposed case. We included a
mandatory “wash-in” period of 12 months before cohort entry to
ensure adequate time to capture true incident outcome diagnoses, as
well as other baseline variables (eg, body mass index [BMI] and
smoking).46
Cohort members were followed until the first of the
following events: anxiety or depression diagnosis (depending on
analysis); a diagnosis suggesting an alternative cause for each
outcome (ie, organic depression or dementia for depression
analyses; obsessive-compulsive disorder or post-traumatic stress
disorder for anxiety analyses; and schizophrenia or bipolar
disease for both depression and anxiety analyses); record of a
morbidity code for an atopic eczema diagnosis (for the unex-
posed group); death date recorded in CPRD; end of registra-
tion with practice; last data collection from practice; or the end
of the study (March 31, 2016).
Covariates
Covariate selection was guided by a literature review and con-
struction of a directed acyclic graph to avoid collider bias47,48 (see
this article’s “Directed acyclic graph” section, Figure E2, and
Tables E1 and E2 in the Online Repository at www.jaci-inpractice.
org). Age, calendar period, sex, and level of deprivation (as quintiles
of the Index of Multiple Deprivation score) and ethnic group weredeemed plausibly associated with both exposure and outcome, and
not on the causal pathway (ie, potential confounders). We consid-
ered BMI, smoking status, harmful alcohol use, and high-dose oral
glucocorticoid as possible mediators of the association between
atopic eczema and depression/anxiety. The data sources and defi-
nitions used to identify all covariates are detailed in this article’s
“Algorithms to identify BMI and steroid use data” and “Algorithms
to identify BMI and steroid use data” sections in the Online Re-
pository at www.jaci-inpractice.org and morbidity code lists are
available to download.49Statistical analysis
We assessed the effect of the atopic eczema exposure on each
outcome (depression or anxiety) using Cox regression stratified by
matched set. We included the covariates used for matching in an
initial crude model (implicitly adjusted for sex and general practice
by stratification on matched set, and for age through the underlying
timescale). We then adjusted for the remaining prespecified po-
tential confounders (calendar period and Index of Multiple
Deprivation) in an adjusted model. Finally, we also further adjusted
for potential mediators of the relationship between atopic eczema
and depression/anxiety (BMI; smoking; harmful alcohol and high-
dose oral glucocorticoid use) in a third model. To preserve
matching, analyses only included valid matched sets; that is, entire
matched sets were excluded if the atopic eczemaeexposed indi-
vidual was excluded (because of preexisting outcome diagnosis at
cohort entry, or because of missing BMI or smoking data in the
models including possible mediators of the relationship between
atopic eczema and depression/anxiety), or if no individuals without
atopic eczema remained in the set.
The absolute incidence rates of new depression and anxiety could
be directly calculated among those with atopic eczema, but matching
precluded a similar approach in those without atopic eczema
(because this was not a representative sample of the general popu-
lation). We, therefore, estimated incidence rates in those without
atopic eczema by multiplying rates in those with atopic eczema by
the corresponding estimated hazard ratio (HR) (after inverting it to
compare unexposed with exposed).50 We calculated attributable risks
as the difference between the incidence rates in those with and
without atopic eczema, and the population-attributable risks by
using the estimated HR and assuming the prevalence of atopic
eczema to be 10%.51
We conducted a series of sensitivity analyses to explore possible
sources of bias introduced by: strict definitions of the psychiatric
diagnoses; use of a “mixed” incident and prevalent cohort; differ-
ential practice attendance; or restrictive algorithm-based definitions
of atopic eczema (see Table E3 in this article’s Online Repository at
www.jaci-inpractice.org).
In prespecified secondary analyses, we (1) redefined atopic eczema
exposure using atopic eczema severity as a time-updated variable and
compared incidence rates of depression and anxiety in those with
mild, moderate, or severe atopic eczema to those with no atopic
eczema and (2) explored possible effect modification of the rela-
tionship between atopic eczema and depression/anxiety by age, sex,
and calendar period.
We checked the proportional hazards assumption for the main
analysis models through visual inspection of Schöenfeld residual
plots. All P values reported are based on likelihood-ratio tests, with
99% CI.52 Statistical analysis was performed using Stata, version
15.1 (StataCorp LP, College Station, Texas).
FIGURE 1. Flow diagram showing the creation of the cohort and reasons for exclusion (1998-2016). ONS, Office for National Statistics;
UTS, up-to-standard.
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TABLE I. Characteristics of people with and without atopic eczema at cohort entry for both depression and anxiety cohorts
Characteristic*
Depression cohort Anxiety cohort
Without atopic eczema
(n [ 1,588,277)
With atopic eczema
(n [ 392,433)
Without atopic eczema
(n [ 1,827,908)
With atopic eczema
(n [ 426,430)
Follow-up (y), median (IQR) 4.21 (1.63-8.62) 4.72 (1.86-9.12) 4.18 (1.62-8.6) 4.71 (1.85-9.13)
Sex: female, n (%) 802,909 (50.6) 211,118 (53.8) 981,824 (53.1) 237,527 (55.7)
Age (y), n (%)
18-39 828,072 (52.1) 195,455 (49.8) 941,183 (51.5) 210,764 (49.4)
40-59 355,209 (22.4) 89,126 (22.7) 431,329 (23.6) 100,592 (23.6)
60 404,996 (25.5) 107,852 (27.5) 455,396 (24.9) 115,074 (27.0)
Index of Multiple Deprivation
(quintiles), n (%)
1 (least deprived) 395,025 (24.9) 99,161 (25.3) 443,389 (24.3) 104,672 (24.6)
2 368,687 (23.2) 91,856 (23.4) 419,555 (23.0) 98,500 (23.1)
3 311,975 (19.6) 76,756 (19.6) 360,901 (19.7) 84,121 (19.7)
4 295,103 (18.6) 72,538 (18.5) 346,152 (18.9) 80,198 (18.8)
5 (most deprived) 217,487 (13.7) 52,122 (13.3) 257,911 (14.1) 58,939 (13.8)
BMI (kg/m2), mean  SD 25.74  5.1 26.01  5.3 25.87  5.2 26.18  5.4
Normal (18.5-24.9 kg/m2), n (%) 574,056 (36.1) 147,216 (37.5) 663,955 (36.3) 158,315 (37.1)
Underweight (<18.5 kg/m2), n (%) 40,118 (2.5) 9,830 (2.5) 46,346 (2.5) 10,536 (2.5)
Overweight (25.0-29.9 kg/m2), n (%) 397,525 (25.0) 105,468 (26.9) 460,537 (25.2) 114,921 (27.0)
Obese (30.0 kg/m2), n (%) 209,823 (13.2) 60,643 (15.5) 258,799 (14.2) 70,714 (15.6)
Missing, n (%) 366,755 (23.1) 69,276 (17.7) 398,271 (21.8) 71,944 (16.9)
Smoking status, n (%)
Nonsmoker 833,152 (52.5) 211,240 (53.8) 939,278 (51.4) 222,529 (52.2)
Current/ex-smoker 638,023 (40.2) 168,778 (43.0) 763,295 (41.8) 191,066 (44.8)
Missing 117,102 (7.4) 12,415 (3.2) 125,335 (6.9) 12,835 (3.0)
Harmful alcohol use, n (%) 23,244 (1.5) 7,114 (1.8) 31,639 (1.7) 9,119 (2.1)
High-dose glucocorticoids (20 mg/d
prednisolone equivalent dose), n (%)
65,155 (4.1) 42,738 (10.9) 78,579 (4.3) 47,840 (11.2)
IQR, Interquartile range; SD, standard deviation.
*See this article’s “Definitions for included covariates” section in the Online Repository at www.jaci-inpractice.org for details of variable definitions.
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Baseline characteristics
We identified 3,095,838 adults aged 18 years or older,
including 526,808 with atopic eczema, and matched them to
2,569,030 without eczema (Figure 1). Further exclusions of in-
dividuals with relevant preexisting psychiatric diagnoses on or
before the start of follow-up yielded 2,467,791 participants in
the cohort for analyses with depression as the outcome, and
2,650,629 with anxiety as the outcome (all belonging to “valid
sets,” that is, matched sets with at least 1 exposed and 1 unex-
posed individual). Median follow-up was similar in both cohorts:
4.7 (interquartile range, 1.6-8.6) years for individuals with atopic
eczema and 4.2 (interquartile range, 1.9-9.1) years for those
without atopic eczema (Table I). The mean age of the atopic
eczemaeexposed individuals was 43.9  21.7 years in the
depression cohort and 44.1  21.43 years in the anxiety cohort.
Participants with atopic eczema were less likely to have
missing BMI values or smoking status, compared with those
without atopic eczema, and those with missing information were
more likely to be young and male (see Tables E4 and E5 in this
article’s Online Repository at www.jaci-inpractice.org).
Main analysis
We explored diagnoses compatible with unipolar depression,
generalized anxiety disorder, and panic disorders as the primaryoutcomes. There was a 1.14-fold (99% CI, 1.12-1.16) increase
in the HR for depression in those with atopic eczema compared
with those without, after adjusting for age, sex, general practice,
current calendar period, and Index of Multiple Deprivation at
cohort entry (Table II. For full model, see Table E6 in this
article’s Online Repository at www.jaci-inpractice.org). Atopic
eczema was also associated with a 1.17-fold (99% CI, 1.14-1.19)
increase in the risk of anxiety. Both estimates were attenuated
after additionally adjusting for BMI, smoking status, harmful
alcohol use, and high-dose glucocorticoid use (variables that may
mediate the relationship between atopic eczema and depression/
anxiety) (depression: HR, 1.10; 99% CI, 1.10-1.12; anxiety:
HR, 1.12; 99% CI, 1.10-1.15). The absolute excess risk of
depression/anxiety among those with atopic eczema that could
be considered due to atopic eczema (attributable risk) was 160
per 100,000 person-years with atopic eczema (99% CI,
146-186) for depression and 144 per 100,000 for anxiety (99%
CI, 115-153) although the excess risk of depression/anxiety in
the population that could be considered due to atopic eczema
(population-attributable risk) was 1.4% (95% CI, 1.2-1.6) for
depression and 1.7% (1.4-1.9) for anxiety (see Table E7 in this
article’s Online Repository at www.jaci-inpractice.org) (these
estimates were calculated assuming a 10% prevalence of atopic
eczema and would increase if atopic eczema were more
common).
TABLE II. HRs (99% CI) from Cox regression for the association between atopic eczema and anxiety and depression
Cohort No. Events/PYAR
Minimally adjusted,
HR (99% CI)*
Adjusted,
HR (99% CI)†
Additionally adjusted for potential mediatorsz
No. Events/PYAR HR (99% CI)
Depression
No atopic eczema 1,588,277 102,882/8,935,934 1.00 (reference) 1.00 (reference) 1,054,673 76,638/6,531,745 1.00 (reference)
Atopic eczema 392,433 31,322/2,354,118 1.14 (1.12-1.16) 1.14 (1.12-1.16) 316,332 27,405/2,042,715 1.10 (1.07-1.12)
Anxiety
No atopic eczema 1,818,796 82,137/10,187,499 1.00 (reference) 1.00 (reference) 1,237,423 63,592/7,566,056 1.00 (reference)
Atopic eczema 424,109 24,283/2,543,384 1.17 (1.14-1.19) 1.17 (1.14-1.19) 345,967 21,666/2,223,508 1.12 (1.09-1.15)
IMD, Index of Multiple Deprivation; PYAR, person-years at-risk.
All models were fitted to people with complete data for all included variables. Matched sets without at least 1 individual with atopic eczema and 1 without were excluded. HRs
were estimated from a Cox regression model with current age as the underlying time scale, stratified by matched set (sex, age, and general practice).
*Minimally adjusted model accounted for the matching variables (1,980,710 participants in the depression cohort [1,920,172 unique people] and 2,242,905 in the anxiety cohort
[2,171,784 unique people]).
†The adjusted model additionally included current calendar period (years: 1998-2001, 2002-2006, 2007-2011, and 2012-2016) and quintiles of IMD at cohort entry (same
participants as in the minimally adjusted).
zAdditionally adjusted for potential mediators: BMI (categorized as normal, 18.5-24.9 kg/m2; underweight, <18.5 kg/m2; overweight 25.0-29.9 kg/m2; and obese 30.0 kg/
m2), smoking status, and alcohol and high-dose glucocorticoid use (20 mg/d prednisolone equivalent dose), both as time-updated variables (1,371,005 participants in the
depression cohort [1,322,284 unique people] and 1,583,390 participants in the anxiety cohort [1,583,390 unique people]).
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 8, NUMBER 1
SCHONMANN ETAL 253Our sensitivity analyses showed broadly similar effect esti-
mates—those from the main analysis (Table E3).Secondary analyses
Atopic eczema severity. Regardless of atopic eczema
severity level, we saw evidence for an association between
atopic eczema and both depression and anxiety (Figure 2).
Compared with those without atopic eczema, the risk of
depression increased with increasing atopic eczema severity (P
< .0001 for linearity; P ¼ .3832 for departure from linearity
in the adjusted model; and P ¼ .6983 for departure from
linearity in the model additionally adjusted for potential me-
diators). However, the results of analyses exploring the rela-
tionship between atopic eczema severity and anxiety did not
demonstrate a similarly clear dose-response relationship; for
mild and moderate atopic eczema, there was some evidence of
a similar dose-response increase, but there was strong statis-
tical evidence for departure from linearity (P < .0001) (see
Table E8 in this article’s Online Repository at www.jaci-
inpractice.org).Effect modification by sex, age, and calendar peri-
od. We saw some evidence (P < .0001) for sex modifying the
effect of atopic eczema on depression, with a slightly higher risk
of depression in those with atopic eczema compared with those
without in men (1.19; 99% CI, 1.16-1.23) than in women
(1.11; 99% CI, 1.08-1.13). We saw a similar pattern for risk of
anxiety in those with and without atopic eczema after strati-
fying on sex (HR [99% CI]: men, 1.22 [99% CI, 1.17-1.27];
women, 1.14 [99% CI, 1.11-1.17]; P ¼ .0003 for interaction).
We also saw evidence for effect modification by current age,
with the HR comparing those with atopic eczema to those
without for both depression (P < .0001) and anxiety (P ¼
.0052) being higher in those aged 40 to 59 years, compared
with younger and older age groups. There was no evidence of a
change in the effect of atopic eczema on both depression (P ¼
.3229) and anxiety (P ¼ .287) in different calendar periods (see
Table E9 in this article’s Online Repository at www.jaci-
inpractice.org).DISCUSSION
Main findings
We found that (treated) atopic eczema was associated with a
14% increase in the risk of newly diagnosed depression (adjusted
HR; 99% CI, 1.12-1.16) and a 17% increase in the risk of a
subsequent anxiety diagnosis (adjusted HR; 99% CI, 1.14-1.19).
These associations were only slightly attenuated after further
adjusting for potential mediators of the association between
atopic eczema and anxiety/depression (BMI, smoking status, and
alcohol and high-dose glucocorticoid use) and were present at all
levels of atopic eczema disease severity. Risk of a new depression
diagnosis increased linearly with increasing atopic eczema
severity, providing strong evidence for a dose-response associa-
tion. The outcomes were diagnoses compatible with unipolar
depression, generalized anxiety disorder, and panic disorders, but
we considered broader definitions of depression/anxiety in sub-
sequent sensitivity analyses.
Strengths and limitations
We identified a large, nationally representative sample of
people, the largest reported to date,20,21 ensuring precise effect
estimations and increased generalizability. We used a validated
diagnostic algorithm to identify atopic eczema in primary care,53
and relied on highly specific physician diagnoses rather than self-
reported outcomes.54-56 We chose the covariates included in the
analysis on the basis of a priori reasoning (see this article’s
“Directed acyclic graph” section; Figure E2).48 Although some
chronic conditions may be associated with atopic eczema,57 as
well as with depression/anxiety,58 in the context of this study, we
did not consider these conditions fit the definition for con-
founding because the potential confounder (chronic comorbid-
ity) could be considered to be either a consequence of the
outcome (anxiety/depression), or to mediate the relationship
between exposure and outcome (see this article’s “Directed
acyclic graph” section).
We deemed other factors (ie, BMI, smoking, systemic glu-
cocorticoids, harmful alcohol use) as likely mediators of the effect
of atopic eczema on depression and anxiety, rather than con-
founders; we consequently adjusted for these variables separately.
Atopic eczema may be associated with the later development of
conditions such as cardiovascular disease and various
FIGURE 2. HRs (99% CI) for the association between eczema severity (time-updated) and depression and anxiety. IMD, Index of Multiple
Deprivation. All models were fitted to people with complete data for all included variables. Sets without at least 1 exposed and 1 un-
exposed were excluded. HRs were estimated from a Cox regression model with current age as the underlying time scale, stratified by
matched set (sex, age, and general practice). Aminimally adjustedmodel accounted for the matching variables (1,980,710 participants in
the depression cohort [1,920,172 unique people] and 2,242,905 in the anxiety cohort [2,171,784 unique people]). The adjusted model
additionally included current calendar period (years: 1998-2001, 2002-2006, 2007-1201, and 2012-2016,) and quintiles of IMD at
cohort entry (same participants as in the minimally adjusted). A final model, additionally adjusted for potential mediators, also included
BMI (categorized as normal, 18.5-24.9 kg/m2; underweight, <18.5 kg/m2; overweight 25.0-29.9 kg/m2; obese 30.0 kg/m2), smoking
status, and alcohol and high-dose corticosteroid use (20 mg/d prednisolone equivalent dose), both as time-updated variables
(1,371,005 participants in the depression cohort [1,322,284 unique people] and 1,583,390 in the anxiety cohort [1,583,390 unique
people]). *Compared with no atopic eczema. †Depression: P values were less than .0001 for linearity in all models, and for departure
from linearity were as follows: minimally adjusted P ¼ .3810; adjusted P ¼ .3832; and additionally adjusted for potential mediators P ¼
.6983. zAnxiety: P values were less than .0001 for linearity in all models, and less than .0001 for departure from linearity in all models.
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chronic comorbidity was beyond the scope of our analysis.
The study also has several limitations. The algorithm we used
to define atopic eczema excluded untreated individuals, reducing
its sensitivity to detect milder cases.59 This limitation was miti-
gated by the availability of primary care data, because 97% of
those with atopic eczema in the United Kingdom are managed in
primary care,60,61 and by including emollients, which are
routinely prescribed for atopic eczema in the United Kingdom.62
The results also remained robust in sensitivity analyses using less-
restrictive atopic eczema definitions. Analyses stratified by atopic
eczema severity provided further reassuring evidence of an asso-
ciation between atopic eczema and anxiety/depression even
among mild cases. However, our definition of atopic eczema
severity might have misclassified individuals with severe atopic
eczema as having less severe disease if they refused medical
therapy.63 Misclassification of disease status or severity may have
overestimated or underestimated the real association between
severity of eczema and anxiety/depression because early symp-
toms of depression/anxiety could influence diagnostic and
treatment preferences. However, general practitioners recorded
their depression/anxiety diagnoses independently and prospec-
tively, so reverse causality likely affected all study participants
equally regardless of atopic eczema status (ie, nondifferential
misclassification, suggesting bias toward the null rather than a
spurious association).
A further limitation of our eczema severity definition was that
we were unable to capture symptom reduction or resolution
(absence of a record for eczema does not necessarily meanabsence in symptoms). Consequently, we considered individuals
as having moderate or severe disease from the date they met the
respective definition, and may therefore have wrongly classified
people as having moderate/severe eczema when their symptoms
had reduced or resolved. The result of wrongly classifying in-
dividuals as having more severe disease when their symptoms had
actually remitted would only be to dilute the effect of eczema
severity on depression/anxiety and bias our effect estimate to
null.
Follow-up began in adulthood, resulting in a mixed cohort of
prevalent and incident (newly diagnosed) atopic eczema cases,
introducing possible bias due to left truncation (ie, the possibility
of an outcome event occurring before cohort entry), with
consequent underestimation or overestimation of the effect of
atopic eczema on depression and anxiety. However, following
only incident cases when exploring predominantly adult-onset
outcomes would have shortened follow-up and limited the
study’s power. In addition, the exact onset date of a relapsing
condition such as atopic eczema cannot be captured accurately in
routinely collected data. In such circumstances, a dynamic cohort
including prevalent cases is preferred.64 A sensitivity analysis
offered evidence against bias introduced by including both
“incident” and prevalent atopic eczema cases in our cohort
because it showed broadly similar results in those with prevalent
atopic eczema and those more likely to have new-onset atopic
eczema.
Smoking status and/or BMI were not recorded for some study
participants, and it is likely that whether smoking status/BMI
was recorded or not was dependent on having atopic eczema or
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smoking status are often captured opportunistically and are
therefore more likely to be recorded in those who consult their
general practitioner more frequently (due to health-seeking
behavior or chronic conditions).65 Although previous studies
suggested no clear-cut association between physical illness and
detection of psychiatric diagnoses in primary care,66,67 the pos-
sibility of selection bias when applying complete case analysis (ie,
including only those with complete data) remains. In our study,
this did not affect the main analysis, because the variables con-
taining missing data were not included in the main adjusted
analysis (they were considered as potential mediators). Compa-
rable results from the model including smoking and BMI also
provide evidence against substantial bias introduced by missing
data. Finally, general practitioners do not routinely record pa-
tients’ quality of sleep, and we were not able to assess the extent
to which itch-related sleep disturbances mediate the development
of depression and anxiety among people with atopic eczema.30
Comparisons to existing literature
An association between atopic eczema, depression, and anxiety
has been described in cross-sectional and case-control studies, in
which the temporal sequence (ie, whether atopic eczema precedes
depression or anxiety, or vice versa) could not be determined.16-
22 The few longitudinal studies that addressed this question had
inconsistent results.32-34 These studies were limited by short
follow-up windows34; inclusion of selected, nonrepresentative
populations (eg, male military conscripts34 or secondary care
diagnoses32,33); no account of atopic eczema disease severity32,34;
low-quality or no individual-level information on lifestyle vari-
ables32,34; and reliance on disease-specific medication usage as a
nonspecific proxy measure to ascertain depression and anxi-
ety.33,34 Notably, a recent Danish cohort study demonstrated
point estimates that were in line with the estimates reported in
our study, but the association was not evident in the adjusted
models that included health care consumption.33
Interpretation and clinical implications
Atopic eczema, like several other chronic conditions,58 is
associated with depression/anxiety. The link to chronic mental
illness further supports the view of atopic eczema as a systemic
disorder.68 Our results suggest that the association between
atopic eczema and depression/anxiety is not substantially medi-
ated through glucocorticoid treatment, obesity, smoking, or
harmful alcohol intake. Evidence against a dose-response asso-
ciation between atopic eczema severity and anxiety could not
only imply different pathophysiological mechanisms but also
reflect misclassification of outcome, because the anxiety outcome
was more heterogeneously defined. Our findings suggest that
atopic eczema was more strongly associated with depression and
anxiety in those aged 40 to 59 years (compared with younger and
older age groups). However, it is unclear why; further research
could investigate possible explanations for differences in the as-
sociation between atopic eczema and depression/anxiety risk in
those at different ages (eg, different age-specific coping strategies,
or increased health care contacts due to active cardiovascular
screening in that age group). Future research could also support
our findings of a dose-response association between atopic
eczema and depression/anxiety by including people with more
severe forms of these conditions (eg, identified using pre-
scriptions for antidepressants and anxiolytic medications).Although our results apply directly to UK primary care, they
are likely to be relevant in other settings, especially where there is
primary careeoriented universal access to health care. Mental
illness is underdiagnosed in people with skin or other chronic
diseases,69-71 but their detection and treatment might improve
atopic eczema control by facilitating better adherence to skin
disease treatment,72 or through direct anti-inflammatory actions
of antidepressants.73 Current UK guidelines address only the
management of atopic eczema in children, emphasizing the
importance of assessing the psychosocial well-being and quality
of life.74 Recent guidelines from the European Academy of
Dermatology and Venereology comment briefly on the influence
of psychological and emotional factors on the clinical course of
atopic eczema.5 Neither of these guidelines mentions the long-
term mental health implications of atopic eczema. Our find-
ings suggest that depression and anxiety should be addressed
explicitly in future guideline updates. Further research is needed
to explore and define possible mediators; to characterize sub-
populations at increased risk (eg, those with adult-onset atopic
eczema, or those with more active variants of the disease); and to
elucidate the feasibility and effectiveness of screening, early
detection, and prevention of depression and anxiety among those
with atopic eczema.
CONCLUSIONS
Individuals affected with atopic eczema were more likely to
develop depression and anxiety, regardless of atopic eczema
severity. Strong evidence for a dose-response relationship be-
tween atopic eczema severity and depression supports a causal
association. These results highlight the importance of a
comprehensive bio-psycho-social approach to limit common
mental disorders in those with atopic eczema and could guide
recommendations for the management of atopic eczema.
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METHODS
Codes and treatments used in algorithm definition of
atopic eczema
Using a validated algorithm,E1 atopic eczema diagnosis was
determined by a combination of any recorded atopic eczema
diagnostic code in primary care (CPRD, using Read codes) or
inpatient hospital admission data (HES, using International
Classification of Diseases, Tenth Revision codes recorded in any
diagnostic position of any episode of care), and 2 atopic eczema
therapies (recorded on separate days in primary care or hospital
records).
To avoid immortal-time bias, the date of diagnosis was set as
the date of the latest recorded component (ie, atopic eczema
diagnostic code or second record for atopic eczema therapy) in
the algorithm.
By default, all individuals with atopic eczema were classified as
having mild disease. They could be recategorized as having
moderate atopic eczema from the earliest of (1) second potent
topical steroid treatment within a year or (2) first calcineurin
inhibitor treatment. Mild or moderate cases could be recatego-
rized as severe, from the earliest of (1) first systemic treatment for
atopic eczema excluding oral glucocorticoids (ie, a record of a
prescription for cyclosporine, azathioprine, mycophenolate, or
methotrexate), or (2) first phototherapy code, or (3) first referral
to secondary care for atopic eczema.
Using electronic health records allowed us to conduct a
population-based analysis powered to explore the association
between atopic eczema, and depression and anxiety. However,
the analysis was limited to data routinely captured in primary
care, which does not include objective assessment of patients’
eczema disease severity using validated scoring systems (eg,
Eczema Area and Severity Index and SCORing Atopic Derma-
titis).E2 To date, there are no validated measures for ascertaining
the severity of atopic eczema using routinely collected data.E3
However, the approach we used to overcome this limitation
(ie, use of prescribed therapies) is commonly used in the
dermato-epidemiology literature.E4-E9
In the United Kingdom, for example, systemic treatments
may be initiated only by dermatologists,E10 making this proxy
measure a highly specific one, because it implies assessment by a
trained specialist. Although this method may misclassify in-
dividuals with severe eczema who declined therapy,E11 findings
from secondary care registries suggest that 60% to 80% of
specialist-diagnosed severe eczema cases did have a history of
systemic treatment.E12,E13 Findings from recent publications also
support the validity of this approach: A positive predictive value
of 93.6% was demonstrated for the diagnosis of severe atopic
eczema using Israeli health records,E4 and a Danish validation
study assessing a similar approach among patients with psoriasis
suggested 91% sensitivity and 83% specificity for detection of
severe disease.E14
Relying on prescribed therapies as a proxy measure for disease
severity may not be fully calibrated with other established scores,
making severity-stratumespecific estimates harder to interpret.
However, a prescribed treatment criterion is likely to perform
well in separating those with a more severe manifestation (ie,
good discrimination). Because of the prospective nature of datacollection in our study, it seems unlikely that any misclassifica-
tion of eczema severity would be differentially associated with the
future outcome, nor does it seem to be of a magnitude large
enough to substantially bias the effect estimate. In such cir-
cumstances, an estimate of trend would be biased downwards,E15
which would only strengthen the validity of a demonstrated
biological gradient.
Our choice of treatments used to define moderate and severe
atopic eczema is broadly consistent with previous similar
attempts,E4-E9 but also reflects some international variability in
prescription practices. For example, although topical calcineurin
inhibitors are indeed recommended for use in mild disease by
recent European guidelines,E16 they are not used for this indi-
cation in the United Kingdom (where our study is set). The
European Medicines Agency has issued a recommendation for
cautious use of topical tacrolimus and pimecrolimus due to po-
tential risks of skin cancer and lymphoma.E17 In the United
Kingdom, these preparations are not considered as first-line
options for mild atopic eczema, and they can be initiated only
by specialistsE10,E18; consequently, we used a prescription for a
calcineurin inhibitor as a marker of moderate eczema.
Read codes and International Classification of Diseases codes
defining atopic eczema and atopic eczema treatments can be
downloaded.E19
Drugs used for treating eczema.
 emollients
 topical glucocorticoids
 topical tacrolimus and pimecrolimus
 oral glucocorticoids
 azathioprine
 ciclosporin
 methotrexate
 mycophenolate mofetil
Code lists for the outcomes (depression and anxiety)
Development of code lists. The monitoring and man-
agement of depression is financially incentivized in UK primary
care through the Quality and Outcomes Framework,E20 which
uses a list of Read codes to define new occurrences of depres-
sion.E21 This resulted in some standardization of codes used in
general practice, but was also highlighted as a contributing reason
for a growing trend among general practitioners to use symptom
codes for depression (eg, “depressive symptoms” and “Low
mood”) rather than definitive diagnostic codes (eg, “major
depression”).E22,E23 Symptom codes are also increasingly used by
general practitioners in the United Kingdom for patients with
anxiety, despite the fact that anxiety diagnosis and treatment are
not included in the Quality and Outcomes Framework. This
trend possibly reflects diagnostic uncertainty and a reluctance to
stigmatize patients.E24,E25
We compiled preliminary lists of potential codes using key-
words from the Medical Subjects Headings list and clinical
knowledge, as previously suggested.E26,E27 This initial list of
codes was compared with and augmented by a code list from the
Clinical research using Linked Bespoke studies and Electronic
health Records website (a platform that aims to offer researchers
predefined code lists and algorithms to identify clinical pheno-
types using electronic health record data)E28 and previously
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iety.E29,E31-E33 Subsequently, we categorized the relevant codes
into several subcategories, on the basis of clinical knowledge,
literature review, and the expert opinion of several coauthors
experienced in general practice (Y.S.), UK clinical practice and
EHR research (S.M.L., J.F.H., and K.E.M.), and psychiatry and
psychiatric epidemiology using electronic health record data
(J.F.H.). The list was finalized through a discussion and
consensus process.
Codes for depression were categorized as follows:
1. “Core” codes: Compatible with “classic unipolar” depression
diagnoses, of various severities.E34 Broadly following the
Quality and Outcomes Frameworkeeligible diagnoses,E21
and in line with previous publications.E29-E32
2. Symptom codes.
3. Nondefinitive codes: Including broader definitions of
depression, depression due to transient causes, and
depression-related administrative codes.
4. History codes: Asserting a history of depression
We used a similar framework to define incident anxiety cases.
Codes compatible with generalized anxiety disorder and panic
disorder were considered as “core” diagnoses. Codes for specific
phobias were included in the nondefinite category.E24,E29,E32,E33
We used codes classified as core codes to define the primary
outcomes in the main analyses and explored the possible intro-
duction of bias through sensitivity analyses (Table E2).
Individuals were excluded from the depression or anxiety
cohort after matching if they had a relevant “core,” “symptom,”
or “nondefinitive” code recorded at any time before cohort entry
(ie, those with previous depression were excluded from the
depression cohort, and those with previous anxiety were excluded
from the anxiety cohort). Individuals with a code for a clinical
term including a “history of” anxiety or depression recorded at
any time were also excluded from the relevant cohort, because
the timing of their diagnosis could not be ascertained.
The recording of our depression/anxiety outcomes is likely to
be biased among those with codes compatible with alternative
etiologies for the outcome (ie, organic depression or dementia for
the depression cohort, obsessive-compulsive disorder or post-
traumatic stress disorder for the anxiety cohort, and schizo-
phrenia or bipolar disease for both cohorts). We, therefore,
excluded people with these conditions if diagnosed before the
index date, and censored participants upon a subsequent diag-
nosis (such alternative diagnoses were, by an order of magnitude,
less frequent than depression/anxiety). If excluded individuals
were in the atopic eczemaeexposed group at baseline, their
respective matched unexposed individuals were also excluded.
Read codes and International Classification of Diseases codes
can be downloaded.E19
Read codes used to define bipolar disease and schizophrenia
were taken from the Clinical research using Linked Bespoke
studies and Electronic health Records website.E28
Directed acyclic graph
A review of the literature revealed several conditions associated
with atopic eczema: age,E35-E39 female sex,E36-E41 socioeconomic
status,E35,E36 ethnicity, health care interactions/health anx-
iety,E35,E41-E43 obesity,E44 smoking status,E36 alcohol
use,E36,E38,E45 diabetes,E8,E36,E46 malignancies,E36,E46 and
chronic conditions (including asthma, cardiovascular diseases,attention deficit/hyperactivity disorder, rheumatoid arthritis,
renal diseases, and inflammatory bowel disorder-
s).E7,E8,E36,E46,E47 To guide covariate selection a priori, and to
avoid collider bias, we constructed a directed acyclic graph
(Figure E2).E48
Chronic diseases could play a mediating role in the association
between atopic eczema and depression/anxiety, but could also be
more likely to be diagnosed among those with depression/anxi-
ety, and therefore introduce collider bias. Chronic comorbidities
were, therefore, not included in our analyses.
A potential confounder (1) must be a risk factor for the
outcome (ie, a cause, or surrogate for a cause, of depression/
anxiety); (2) must be associated with the exposure (ie, atopic
eczema); and (3) cannot be an intermediate step on the causal
path between exposure and outcome (ie, it must not mediate the
association between atopic eczema and depression/anxiety) nor
be a consequence of the outcome (depression/anxiety).E49
Although some chronic conditions may be associated with
atopic eczema,E50 as well as with depression/anxiety,E51 in the
context of this study, we did not consider that these chronic
conditions fit the definition for confounding because the po-
tential confounder (chronic comorbidity) could be considered to
either be a consequence of the outcome (anxiety/depression) or
to mediate the relationship between exposure and outcome. Even
though our study specifically excluded preexisting psychiatric
diagnoses, there is a possibility of undiagnosed mental illness, so
chronic conditions could still be potential consequences of
anxiety or depression because (1) most primary care patients with
depression initially present with somatic symptoms,E52 and
increased general practitioner attendance is associated with earlier
diagnosis of chronic conditions,E53,E54 and (2) depression/anxi-
ety (ie, the outcomes) are well-established independent risk fac-
tors for chronic medical conditions.E55-E58 Therefore, we did not
adjust for chronic comorbidities as confounders, because
adjusting for factors that may be influenced by both the exposure
and the outcome would introduce collider bias.E49,E59
Alternatively, we could regard chronic comorbidities as medi-
ators of the relationship between atopic eczema (exposure) and
anxiety/depression (outcomes). By adjusting for lifestyle factors (ie,
BMI, smoking, and harmful alcohol use) as potential mediators,
we were able to capture, at least some of, the effect of atopic eczema
on chronic comorbidities (ie, considering lifestyle factors as being
on the causal pathway between atopic eczema and chronic
comorbidities such as cardiovascular disease). Of note here, addi-
tional adjustment for potential mediators (Table II) only slightly
attenuated the effect of atopic eczema on anxiety/depression,
suggesting that further adjustment for chronic comorbidities may
have limited impact. So, although atopic eczema may predict
conditions such as cardiovascular disease and various malig-
nancies,E7,E50 exploring the potential mediating role of chronic
comorbidity was beyond the scope of our analysis.
Definitions for included covariates
The date of birth was set as July 1 for all participants, because
CPRD supplies year of birth only (to ensure patient anonymity).
Calendar period was categorized as 1998 to 2001, 2002 to 2006,
2007 to 2011, and 2012 to 2016, to account for changes in
clinical, diagnostic, and administrative practices over the study
period that may have influenced the measurement of exposure,
outcomes, and other covariates. Socioeconomic deprivation was
assigned through categorizing each participant’s 2007 Index of
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IMD is an index of deprivation updated by the Department for
Communities and Local Government every few years, combining
information from 7 domains: income, employment, health and
disability, education, barriers to housing and services, living
environment, and crime.E60 IMD data are available for the years
2004, 2007, 2010, and 2015. We chose 2007 as the midpoint of
the study (January 1998 to March 2016). IMD was assigned on
the basis of individual postcode of residence, or on 2010
practice-location if other data were unavailable.
BMI was categorized as underweight (<18.5 kg/m2), normal
(20-24 kg/m2), overweight (25-29 kg/m2), and obese (>30 kg/
m2), in line with the World Health Organization catego-
rization.E61 Harmful alcohol use was based on relevant morbidity
coding or prescriptions for drugs used to maintain alcohol absti-
nence, with status changing at first primary care record suggesting
harmful alcohol use.High-dose oral glucocorticoid usewas defined
as greater than or equal to 20 mg/d prednisolone equivalent dose,
for the duration of the patients’ prescription and 3months after the
end of the prescription (glucocorticoids included deflazacort,
dexamethasone, prednisone, prednisolone). Smoking status and
BMIwere defined on the basis of status recorded closest to the date
an individual entered the cohort. Missing doses of glucocorticoids
were completed by using data from the entire data set. (See
"Algorithms to identify BMI and steroid use data" for a full
description of the data completion algorithms.)
For a sensitivity analysis, ethnicity was included as covariate,
based on a previously validated algorithm.E62 Ethnicity was
assigned to 5 categories: white, South Asian, black, other, or
mixed. First, the most common ethnicity in CPRD was used,
then the latest ethnicity in CPRD was used where several eth-
nicities were recorded equally, and finally HES ethnicity was
used where CPRD ethnicity was missing. Because the quality of
the recording for ethnicity was acceptable only from 2006
onwards,E62 we restricted this analysis to those registering with
the CPRD general practice after January 1, 2006.
Read codes and International Classification of Diseases codes
used to identify covariates can be downloaded.E19Algorithms to identify BMI and steroid use data
Body mass index. Read codes for BMI category were not
used (because they are rarely recorded). Instead BMI was
calculated using height and weight measures recorded closest to
the cohort entry date (1 year before to 1 month after the cohort
entry date; if not available, then the nearest in the year following
cohort entry was taken; if not available, then the nearest value in
the year before cohort entry was taken; if not available, then
nearest weight value recorded after the first year was used). We
regarded improbable values of BMI (BMI < 10 kg/m2 or BMI >
60 kg/m2) as errors, and therefore considered these data as
missing. Smoking status was categorized as current/ex or none on
the basis of record closest to cohort entry date.Glucocorticoid dose. The daily dose of oral glucocorticoid
was calculated as the number of pills prescribed numeric daily
dose (NDD)  dose per tablet. Where NDD was missing, a
“hot-deck” style imputation method was adopted, which
replaced missing data with comparable data from the same set.
An extra binary variable for quantity of tablets per prescription
was created, categorizing quantity about the median number into
low and high. If a patient had any other record with the same
quantity and dose per tablet, the median NDD among those
records was used where NDD was missing. If a patient had no
recorded NDD but had any other record of the same dose per
tablet and quantity as a binary variable, the median NDD among
those records was used. If a patient did not have a recorded
NDD or quantity, but had records for the same dose per tablet,
then the median NDD among those records was used. If there
was no record of NDD, dose per tablet or quantity, but there
were other patients in the data set in the same 5-year age band, of
the same sex, with the same dose per tablet and quantity, the
median NDD for those records was used. Finally, if none of the
above were possible, patients in the data set in the same 5-year
age band, of the same sex, with the same dose per tablet and
quantity as a binary variable, the median NDD among these
records was used.
FIGURE E1. Visual representation of the cohort entry criteria and follow-up process.
FIGURE E2. Directed acyclic graph illustrating implicitly assumed causal structure underlying our adjusted models.
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TABLE E1. Univariable associations between covariates and depression
Variable Events/PYAR Rate/100,000 PYAR HR (99% CI)
Atopic eczema exposure
Without atopic eczema 102,882/8,935,934 1,151 (1,142-1,161) 1.00 (reference)
With atopic eczema 31,322/2,354,118 1,331 (1,311-1,350) 1.14 (1.11-1.16)
Atopic eczema severity
Unexposed 102,882/8,935,934 1,151 (1,142-1,161) 1.00 (reference)
Mild 19,116/1,436,377 1,331 (1,306-1,356) 1.10 (1.07-1.12)
Moderate 10,301/786,352 1,310 (1,277-1,344) 1.19 (1.15-1.23)
Severe 1,905/131,389 1,450 (1,367-1,538) 1.25 (1.16-1.35)
Sex
Male 49,110/5,599,286 877 (867-887) NA
Female 85,094/5,690,766 1495 (1482-1509) NA
Age at cohort entry (y)
18-19 24,147/1,511,015 1,598 (1,572-1,625) 1.00 (reference)
20-29 26,094/1,698,066 1,537 (1,512-1,561) 1.00 (0.88-1.14)
30-39 23,230/1,817,250 1,278 (1,257-1,300) 1.10 (0.84-1.44)
40-49 17,298/1,599,240 1,082 (1,061-1,103) 1.01 (0.65-1.57)
50-59 12,621/1,569,384 804 (786-823) 1.29 (0.71-2.36)
60-69 11,943/1,542,594 774 (756-793) 2.30 (1.16-4.56)
70-79 12,633/1,133,250 1,115 (1,090-1,141) 3.50 (1.69-7.25)
80 6,238/419,254 1,488 (1,440-1,537) 3.95 (1.82-8.59)
Calendar period (y)
1998-2001 22,063/1,422,827 1,551 (1,524-1,578) 1.00 (reference)
2002-2006 37,260/2,937,645 1,268 (1,252-1,285) 0.75 (0.64-0.87)
2007-2011 42,449/3,973,737 1,068 (1,055-1,082) 0.59 (0.49-0.71)
2012-2016 32,432/2,955,843 1,097 (1,082-1,113) 0.56 (0.46-0.69)
IMD (quintiles)
1 (least deprived) 28,280/2,942,268 961 (947-976) 1.00 (reference)
2 28,468/2,687,862 1,059 (1,043-1,075) 1.11 (1.08-1.14)
3 26,471/2,229,329 1,187 (1,169-1,206) 1.22 (1.19-1.26)
4 27,669/1,995,052 1,387 (1,366-1,409) 1.46 (1.41-1.51)
5 (most deprived) 23,316/1,435,541 1,624 (1,597-1,652) 1.72 (1.66-1.79)
BMI (kg/m2), mean  SD
Normal (18.5-24.9 kg/m2) 3,613  206,460 1,750 (1,677-1,827) 1.00 (reference)
Underweight (<18.5 kg/m2) 47,272  3,898,062 1,213 (1,198-1,227) 0.85 (0.80-0.90)
Overweight (25.0-29.9 kg/m2) 32,541  2,989,894 1,088 (1,073-1,104) 0.89 (0.84-0.94)
Obese (30.0 kg/m2) 21,096  1,521,982 1,386 (1,362-1,411) 1.08 (1.01-1.14)
Smoking status
Nonsmoker 61,985/6,112,858 1,014 (1,004-1,025) 1.00 (reference)
Current/ex-smoker 66,260/4,456,536 1,487 (1,472-1,502) 1.60 (1.57-1.63)
Harmful alcohol use*
No 129,457/11,080,950 1,168 (1,160-1,177) 1.00 (reference)
Yes 4,747/209,102 2,270 (2,187-2,357) 2.57 (2.43-2.71)
High-dose glucocorticoids* (20 mg/d prednisolone equivalent dose)
No 132,592/11,219,476 1,182 (1,173-1,190) 1.00 (reference)
Yes 1,612/70,576 2,284 (2,142-2,435) 2.10 (1.92-2.29)
NA, Not applicable/available; PYAR, person-years at-risk.
Univariable HRs are derived from Cox regression models with current age as the underlying timescale, stratified by matched set (sex, age, and general practice). Models were
fitted to patients with complete data who are included in valid sets (ie, with at least 1 exposed and 1 unexposed individual).
*Measured as a time-updated variable.
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TABLE E2. Univariable associations between covariates and anxiety
Variable Events/PYAR Rate/100,000 PYAR HR (99% CI)
Atopic eczema exposure
Without atopic eczema 82,137/10,187,499 806 (799-814) 1.00 (reference)
With atopic eczema 24,283/2,543,384 955 (939-971) 1.17 (1.14-1.19)
Atopic eczema severity
Unexposed 82,137/10,187,499 806 (799-814) 1.00 (reference)
Mild 15,093/1,543,672 978 (957-998) 1.14 (1.11-1.17)
Moderate 7,822/853,452 917 (890-944) 1.21 (1.17-1.26)
Severe 1,368/146,259 935 (872-1003) 1.14 (1.04-1.25)
Sex
Male 32,586/5,928,234 550 (542-558) NA
Female 73,834/6,802,649 1,085 (1,075-1,096) NA
Age at cohort entry (y)
18-19 18,218/1,582,297 1,151 (1,130-1,174) 1.00 (reference)
20-29 22,028/1,950,021 1,130 (1,110-1,149) 0.80 (0.69-0.92)
30-39 20,658/217,9519 948 (931-965) 0.66 (0.51-0.86)
40-49 14,555/1,892,615 769 (753-786) 0.66 (0.44-0.99)
50-59 10,918/1,779,862 613 (598-629) 0.51 (0.29-0.90)
60-69 9,436/1,668,280 566 (551-581) 0.62 (0.32-1.19)
70-79 7,603/1,210,115 628 (610-647) 0.72 (0.35-1.48)
80 3,004/468,173 642 (612-673) 0.86 (0.39-1.93)
Calendar period (y)
1998-2001 16,323/1,572,503 1,038 (1,017-1,059) 1.00 (reference)
2002-2006 28,605/3,294,860 868 (855-881) 0.96 (0.80-1.15)
2007-2011 32,291/4,494,729 718 (708-729) 0.83 (0.67-1.03)
2012-2016 29,201/3,368,791 867 (854-880) 0.87 (0.69-1.10)
IMD (quintiles)
1 (least deprived) 23,246/3,239,958 717 (705-730) 1.00 (reference)
2 23,013/2,989,450 770 (757-783) 1.09 (1.05-1.22)
3 20,698/2,535,226 816 (802-831) 1.15 (1.11-1.19)
4 21,398/2,296,647 932 (915-948) 1.30 (1.25-1.35)
5 (most deprived) 18,065/1,669,602 1,082 (1,061-1,103) 1.42 (1.36-1.48)
BMI (kg/m2), mean  SD
Normal (18.5-24.9 kg/m2) 3,109  236,632 1,314 (1,255-1,376) 1.00 (reference)
Underweight (<18.5 kg/m2) 40,808  4,412,253 925 (913-937) 0.86 (0.81-0.91)
Overweight (25.0-29.9 kg/m2) 25,695  3,365,057 764 (751-776) 0.85 (0.80-0.90)
Obese (30.0 kg/m2) 16,016  1,823,430 878 (861-896) 0.90 (0.84-0.96)
Smoking status
Nonsmoker 51,195/6,778,933 755 (747-764) 1.00 (reference)
Current/ex-smoker 51,622/5,186,043 995 (984-1007) 1.44 (1.42-1.47)
Harmful alcohol use*
No 102,616/12,465,556 823 (817-830) 1.00 (reference)
Yes 3,804/265,326 1,434 (1,375-1,495) 2.32 (2.18-2.46)
High-dose glucocorticoids* (20 mg/d prednisolone equivalent dose)
No 105,057/12,646,811 831 (824-837) 1.00 (reference)
Yes 1,363/84,071 1,621 (1,512-1,738) 2.12 (1.92-2.34)
NA, Not applicable/available; PYAR, person-years at-risk.
Univariable HRs are derived from Cox regression models with current age as the underlying timescale, stratified by matched set (sex, age, and general practice). Models were
fitted to patients with complete data who are included in valid sets (ie, with at least 1 exposed and 1 unexposed individual).
*Measured as a time-updated variable.
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TABLE E3. Description, justification, and summary results of sensitivity analyses
Analysis Description Justification
Depression Anxiety
No. Events/PYAR Adjusted HR* (99% CI) No. Events/PYAR Adjusted HR* (99% CI)
Main analysis 1,980,710 134,204/11,290,052 1.14 (1.12-1.16) 2,242,905 106,420/12,730,883 1.17 (1.14-1.19)
Sensitivity
analysis 1
Repeating the primary analysis
using progressively less-strict
definitions of psychiatric
diagnoses
To explore potential bias
introduced by low sensitivity to
detect psychiatric diagnoses in
electronic health records, as
well as by general
practitioner’s use of symptom
codes, instead of diagnostic
codes
(1a) Initially including symptom
codes in the definitions of
outcomes
1,980,710 211,534/10,970,276 1.16 (1.14-1.17) 2,242,905 175,874/12,420,852 1.18 (1.16-1.20)
(1b) Subsequently also adding
“nondefinitive” diagnostic
codes
1,980,710 227,393/10,908,249 1.15 (1.14-1.17) 2,242,905 202,679/12,353,235 1.18 (1.16-1.20)
Sensitivity
analysis 2
Repeating the primary analysis
separately for prevalent and
incident atopic eczema cases.
Stratifying the analysis on the
time since the initial diagnosis
(0-4 or 5 y)
To separate “true prevalent” cases
from likely incident atopic
eczema cases to explore
possible bias due to the choice
of a “prevalent” cohort design
(2a) “Incident” cohort
(2b) “Prevalent” cohort
1,431,318
549,392
97,372/8,445,494
36,832/2,844,558
1.17 (1.15-1.20)
1.05 (1.01-1.09)
1,646,703
596,202
77,545/9,614,471
28,875/3,116,412
1.19 (1.16-1.22)
1.10 (1.06-1.15)
Sensitivity
analysis 3
Repeating the primary analysis
including only those who
consulted their general
practitioner in the year before
cohort entry
To explore potential bias due to
differential recording of
exposure, covariates, and
outcomes among practice
attenders and nonattenders.
Robust effect implies
insensitivity to bias introduced
by varying degrees of health
care contact
1,825,694 125,472/10,460,654 1.16 (1.14-1.18) 2,086,308 100,225/11,882,522 1.19 (1.16-1.21)
Sensitivity
analysis 4
Repeating the primary analysis
on redefined cohorts with a
less-restrictive atopic eczema
definition: atopic eczema
diagnosis was ascertained
using only atopic eczema
diagnostic codes, with no
requirement for a therapeutic
code
To explore the sensitivity of the
results to the definition of
atopic eczema (eg, those with
childhood atopic eczema may
have been erroneously
excluded from the primary
analysis if they switched
practice in adulthood, and did
not require further treatments)
2,514,107 173,793/14,708,229 1.07 (1.05-1.09) 2,838,141 135,719/16,515,260 1.10 (1.08-1.12)
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Sensitivity
analysis 5
Repeating the primary analysis on
redefined cohorts with a less-
restrictive definition for those
without atopic eczema
(unexposed): individuals with
an atopic eczema diagnosis but
without 2 further eczema
treatments were considered not
to have atopic eczema, and
could therefore be included in
the pool of unexposed
participants. The cohort of
patients with atopic eczema
remained the same (ie, eczema
was defined as having at least 1
diagnostic code and 2
treatment codes)
To explore the sensitivity of the
results to the definition of
atopic eczema
2,002,613 135,552/11,329,039 1.14 (1.12-1.16) 2,267,537 107,660/12,771,273 1.16 (1.14-1.19)
Sensitivity
analysis 6
Additionally adjusting for
ethnicity (white, South Asian,
black, other, or mixed,
identified from CPRD and HES
data). Analysis was restricted
to those registered in 2006 or
later, because ethnicity
recording before 2006 is
selective, and of low qualityE62
To examine whether the omission
of ethnicity from the primary
analysis may have introduced
bias, because reliable ethnicity
data exists only for that period
276,853 8,251/649,041 1.16 (1.06-1.26) 340,161 8,481/80,4170 1.29 (1.18-1.40)
PYAR, Person-years at-risk.
All models were fitted to patients with complete data for all included variables. Sets without at least 1 exposed and 1 unexposed were excluded. HRs were estimated from a Cox regression model with current age as the underlying timescale,
stratified by matched set (sex, age, and general practice), and adjusted for current calendar period (years: 1998-2001, 2002-2006, 2007-2011, and 2012-2016,) and quintiles of IMD at cohort entry.
*All HRs are for the outcome (ie, depression/anxiety) among those with atopic eczema, compared with those without atopic eczema.
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TABLE E4. Exploring missing data—distribution of baseline characteristics in depression study population (overall, those with complete data, those with missing BMI, and those with
missing smoking status)
Atopic eczema status, n (%)
Overall depression
sample
(n [ 1,980,710
[100%])
Mediation model
sample*
(n [ 1,371,005
[69.2%])
Individuals with
missing BMI
(n [ 436,031
[22.0%])
Individuals with missing
smoking status
(n [ 129,517
[6.5%])
Without atopic
eczema
(n [ 1,588,277
[100%])
With atopic
eczema
(n [ 392,433
[100%])
Without atopic
eczema
(n [ 1,054,673
[66.4%])
With atopic
eczema
(n [ 316,332
[80.6%])
Without atopic
eczema
(n [ 366,755
[23.1%])
With atopic
eczema
(n [ 69,276
[17.65%])
Without atopic
eczema
(n [ 117,102
[7.4%])
With atopic
eczema
(n [ 12,415
[3.2%])
Follow-up (y), median (IQR) 4.21 (1.63-8.62) 4.72 (1.86-9.12) 4.91 (1.95-9.49) 5.26 (2.18-9.88) 2.80 (1.13-6.18) 2.75 (1.14-5.86) 2.30 (0.86-5.23) 1.75 (0.75-3.96)
Sex: female, n (%) 802,909 (50.55) 211,118 (53.80) 593,302 (56.25) 182,005 (57.54) 136,354 (37.18) 25,982 (37.51) 40,402 (34.50) 4,446 (35.81)
Age (y), n (%)
18-19 268,216 (16.89) 74,303 (18.93) 71,409 (6.77) 33,343 (10.54) 151,841 (41.40) 38,048 (54.92) 42,890 (36.63) 6,906 (55.63)
20-29 314,643 (19.81) 64,699 (16.49) 183,603 (17.41) 51,753 (16.36) 78,605 (21.43) 11,823 (17.07) 25,088 (21.42) 1,869 (15.05)
30-39 245,213 (15.44) 56,453 (14.39) 182,352 (17.29) 50,871 (16.08) 39,497 (10.77) 5,087 (7.34) 13,467 (11.50) 802 (6.46)
40-49 181,584 (11.43) 46,172 (11.77) 146,905 (13.93) 42,742 (13.51) 23,994 (6.54) 3,108 (4.49) 8,836 (7.55) 417 (3.36)
50-59 173,625 (10.93) 42,954 (10.95) 147,029 (13.94) 40,500 (12.80) 18,447 (5.03) 2,179 (3.15) 7,006 (5.98) 300 (2.42)
60-69 177,634 (11.18) 44,460 (11.33) 154,768 (14.67) 42,306 (13.37) 15,287 (4.17) 1,903 (2.75) 5,518 (4.71) 286 (2.30)
70-79 143,603 (9.04) 39,351 (10.03) 117,080 (11.10) 36,146 (11.43) 16,782 (4.58) 2,692 (3.89) 6,094 (5.20) 575 (4.63)
80 83,759 (5.27) 24,041 (6.13) 51,527 (4.89) 18,671 (5.90) 22,302 (6.08) 4,436 (6.40) 8,203 (7.01) 1,260 (10.15)
IMD (quintiles), n (%)
1 (least deprived) 395,025 (24.87) 99,161 (25.27) 266,815 (25.30) 80,001 (25.29) 88,989 (24.26) 17,547 (25.33) 28,477 (24.32) 3,164 (25.49)
2 368,687 (23.21) 91,856 (23.41) 247,499 (23.47) 74,522 (23.56) 83,470 (22.76) 15,846 (22.87) 25,338 (21.64) 2,706 (21.80)
3 311,975 (19.64) 76,756 (19.56) 206,425 (19.57) 61,540 (19.45) 71,649 (19.54) 13,673 (19.74) 22,828 (19.49) 2,656 (21.39)
4 295,103 (18.58) 72,538 (18.48) 194,459 (18.44) 58,471 (18.48) 68,535 (18.69) 12,819 (18.50) 22,398 (19.13) 2,270 (18.28)
5 (most deprived) 217,487 (13.69) 52,122 (13.28) 139,475 (13.22) 41,798 (13.21) 54,112 (14.75) 9,391 (13.56) 18,061 (15.42) 1,619 (13.04)
BMI (kg/m2), mean  SD 25.74  5.08 26.01  5.25 25.87  5.06 26.03  5.24 NA NA 24.78  5.60 25.63  5.89
Normal (18.5-24.9 kg/m2), n (%) 574,056 (36.14) 147,216 (37.51) 30,884 (2.93) 9,320 (2.95) NA NA 610 (0.52) 91 (0.73)
Underweight (<18.5 kg/m2) 40,118 (2.53) 9,830 (2.50) 486,260 (46.11) 143,793 (45.46) NA NA 3,829 (3.27) 513 (4.13)
Overweight (25.0-29.9 kg/m2) 397,525 (25.03) 105,468 (26.88) 351,348 (33.31) 103,722 (32.79) NA NA 1,932 (1.65) 332 (2.67)
Obese (30.0 kg/m2) 209,823 (13.21) 60,643 (15.45) 186,181 (17.65) 59,497 (18.81) NA NA 1,106 (0.94) 239 (1.93)
Missing 366,755 (23.09) 69,276 (17.65) NA NA NA NA 109,625 (93.61) 11,240 (90.54)
Smoking status, n (%)
Nonsmoker 833,152 (52.46) 211,240 (53.83) 576,625 (54.67) 169,241 (53.50) 163,523 (44.59) 38,553 (55.65) NA NA
Current/ex-smoker 638,023 (40.17) 168,778 (43.01) 478,048 (45.33) 147,091 (46.50) 93,607 (25.52) 19,483 (28.12) NA NA
Missing 117,102 (7.37) 12,415 (3.16) NA NA 109,625 (29.89) 11,240 (16.22) NA NA
Harmful alcohol use, n (%)† 23,244 (1.46) 7,114 (1.81) 18,235 (1.73) 6,437 (2.03) 2,729 (0.74) 583 (0.84) 546 (0.47) 68 (0.55)
High-dose glucocorticoids, n (%)†,z 65,155 (4.10) 42,738 (10.89) 48,539 (4.60) 35,368 (11.18) 9,732 (2.65) 6,323 (9.13) 1,712 (1.46) 776 (6.25)
IQR, Interquartile range; NA, not applicable/available.
*Individuals with complete data on BMI and smoking status, belonging to a valid set (ie, a set with at least 1 exposed and 1 unexposed individual).
†Status recorded at or before cohort entry.
z20 mg/d prednisolone equivalent dose.
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TABLE E5. Exploring missing data—distribution of baseline characteristics in anxiety study population (overall, those with complete data, those with missing BMI, and those with missing
smoking status)
Atopic eczema status, n (%)
Overall anxiety sample
(n [ 2,254,338 [100%])
Included in the model
additionally adjusted
for potential mediators*
(n [ 1,592,373 [70.1%])
Individuals with missing BMI
(n [ 470,215 [20.9%])
Individuals with
missing smoking
status (n [ 138,170
[6.1%])
Without atopic
eczema
(n [ 1,827,908)
With atopic
eczema
(n [ 426,430)
Without atopic
eczema
(n [ 1,244,303
[68.1%])
With atopic
eczema
(n [ 348,070
[81.6%])
Without atopic
eczema
(n [ 398,271
[21.8%])
With atopic
eczema
(n [ 71,944
[16.9%])
Without atopic
eczema
(n [ 125,335
[6.9%])
With atopic
eczema
(n [ 12,835
[3.0%])
Follow-up (y), median (IQR) 4.18 (1.62-8.57) 4.71 (1.85-9.13) 4.80 (1.91-9.38) 5.21 (2.15-9.85) 2.78 (1.11-6.15) 2.75 (1.14-5.87) 2.28 (0.85-5.16) 1.75 (0.75-3.95)
Sex: female, n (%) 981,824 (53.71) 237,527 (55.70) 737,936 (59.31) 206,628 (59.36) 157,984 (39.67) 28,048 (38.99) 45,792 (36.54) 4,729 (36.84)
Age (y), n (%)
18-19 278,370 (15.23) 75,587 (17.73) 77,429 (6.22) 34,665 (9.96) 154,202 (38.72) 38,118 (52.98) 43,453 (34.67) 6,893 (53.70)
20-29 363,408 (19.88) 71,126 (16.68) 219,418 (17.63) 57,707 (16.58) 86,304 (21.67) 12,401 (17.24) 26,926 (21.48) 1,945 (15.15)
30-39 299,405 (16.38) 64,051 (15.02) 226,984 (18.24) 58,096 (16.69) 45,625 (11.46) 5,534 (7.69) 15,000 (11.97) 864 (6.73)
40-49 224,547 (12.28) 52,644 (12.35) 183,675 (14.76) 48,993 (14.08) 28,124 (7.06) 3,408 (4.74) 9,839 (7.85) 449 (3.50)
50-59 206,782 (11.31) 47,948 (11.24) 176,065 (14.15) 45,339 (13.03) 21,176 (5.32) 2,384 (3.31) 7,738 (6.17) 327 (2.55)
60-69 199,628 (10.92) 47,523 (11.14) 174,165 (14.00) 45,245 (13.00) 16,891 (4.24) 2,042 (2.84) 6,024 (4.81) 303 (2.36)
70-79 157,992 (8.64) 41,379 (9.70) 127,811 (10.27) 37,861 (10.88) 18,891 (4.74) 3,002 (4.17) 6,792 (5.42) 652 (5.08)
80 97,776 (5.35) 26,172 (6.14) 58,756 (4.72) 20,164 (5.79) 27,058 (6.79) 5,055 (7.03) 9,563 (7.63) 1,402 (10.92)
IMD (quintiles), n (%)
1 (least deprived) 443,389 (24.26) 104,672 (24.55) 305,648 (24.56) 85,271 (24.50) 95,192 (23.90) 17,897 (24.88) 29,969 (23.91) 3,203 (24.96)
2 419,555 (22.95) 98,500 (23.10) 287,847 (23.13) 80,701 (23.19) 90,126 (22.63) 16,398 (22.79) 26,988 (21.53) 2,797 (21.79)
3 360,901 (19.74) 84,121 (19.73) 244,871 (19.68) 68,311 (19.63) 78,086 (19.61) 14,301 (19.88) 24,583 (19.61) 2,776 (21.63)
4 346,152 (18.94) 80,198 (18.81) 234,775 (18.87) 65,633 (18.86) 75,275 (18.90) 13,414 (18.65) 24,299 (19.39) 2,347 (18.29)
5 (most deprived) 257,911 (14.11) 58,939 (13.82) 171,162 (13.76) 48,154 (13.83) 59,592 (14.96) 9,934 (13.81) 19,496 (15.56) 1,712 (13.34)
BMI (kg/m2), mean  SD 25.87  5.22 26.18  5.41 25.99  5.21 26.20  5.40 NA NA 24.90  5.65 25.70  5.97
Normal (18.5-24.9 kg/m2), n (%) 663,955 (36.32) 158,315 (37.13) 36,355 (2.92) 10,070 (2.89) NA NA 671 (0.54) 103 (0.80)
Underweight (<18.5 kg/m2), n (%) 46,346 (2.54) 10,536 (2.47) 567,834 (45.63) 155,158 (44.58) NA NA 4,277 (3.41) 541 (4.22)
Overweight (25.0-29.9 kg/m2), n (%) 460,537 (25.19) 114,921 (26.95) 408,820 (32.86) 113,265 (32.54) NA NA 2,230 (1.78) 355 (2.77)
Obese (30.0 kg/m2), n (%) 258,799 (14.16) 70,714 (15.58) 231,294 (18.59) 69,577 (19.99) NA NA 1,300 (1.04) 268 (2.09)
Missing, n (%) 398,271 (21.79) 71,944 (16.87) NA NA NA NA 116,857 (93.24) 11,568 (90.13)
Smoking status, n (%)
Nonsmoker 939,278 (51.39) 222,529 (52.18) 663,686 (53.34) 180,172 (51.76) 175,018 (43.94) 39,251 (54.56) NA NA
Current/ex-smoker 763,295 (41.76) 191,066 (44.81) 580,617 (46.66) 167,898 (48.24) 106,396 (26.71) 21,125 (29.36) NA NA
Missing 125,335 (6.86) 12,835 (3.01) NA NA 116,857 (29.34) 11,568 (16.08) NA NA
Harmful alcohol use† 31,639 (1.73) 9,119 (2.14) 24,994 (2.01) 8,222 (2.36) 3,740 (0.94) 791 (1.10) 697 (0.56) 107 (0.83)
High-dose glucocorticoids†,z 78,579 (4.30) 47,840 (11.22) 59,842 (4.81) 40,269 (11.57) 10,773 (2.70) 6,598 (9.17) 1,908 (1.52) 820 (6.39)
IQR, Interquartile range; NA, not applicable/available.
*Individuals with complete data on BMI and smoking status, belonging to a valid set (ie, a set with at least 1 exposed and 1 unexposed individual).
†Status recorded at or before cohort entry.
z20 mg/d prednisolone equivalent dose.
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TABLE E6. Main analyses—full models for the association between all included variables and anxiety/depression
Included variable
Depression Anxiety
Minimally adjusted
HR (99% CI)
Adjusted
HR (99% CI)
Additionally adjusted
for potential mediators
HR (99% CI)
Minimally adjusted
HR (99% CI)
Adjusted
HR (99% CI)
Additionally adjusted for
potential mediators
HR (99% CI)
Atopic eczema
Without atopic eczema 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
With atopic eczema 1.14 (1.12-1.16) 1.14 (1.12-1.16) 1.10 (1.07-1.12) 1.17 (1.14-1.19) 1.17 (1.14-1.19) 1.12 (1.09-1.15)
Calendar period (y)
1998-2001 NA 1.00 (reference) 1.00 (reference) NA 1.00 (reference) 1.00 (reference)
2002-2006 NA 0.74 (0.64-0.86) 0.76 (0.64-0.91) NA 0.95 (0.79-1.14) 0.95 (0.7-1.16)
2007-2011 NA 0.59 (0.49-0.71) 0.63 (0.51-0.77) NA 0.82 (0.67-1.02) 0.81 (0.64-1.02)
2012-2016 NA 0.55 (0.45-0.68) 0.58 (0.46-0.73) NA 0.86 (0.68-1.08) 0.84 (0.65-1.08)
IMD (quintiles)
1 (least deprived) NA 1.00 (reference) 1.00 (reference) NA 1.00 (reference) 1.00 (reference)
2 NA 1.11 (1.08-1.14) 1.08 (1.04-1.12) NA 1.09 (0.05-1.12) 1.06 (1.02-1.10)
3 NA 1.22 (1.19-1.26) 1.16 (1.12-1.21) NA 1.15 (0.11-1.19) 1.11 (1.07-1.16)
4 NA 1.46 (1.41-1.51) 1.34 (1.29-1.40) NA 1.30 (1.25-1.35) 1.23 (1.18-1.28)
5 (most deprived) NA 1.72 (1.66-1.79) 1.53 (1.46-1.60) NA 1.42 (1.36-1.48) 1.31 (1.25-1.37)
BMI (kg/m2)
Normal NA NA 1.00 (reference) NA NA 1.00 (reference)
Underweight NA NA 0.87 (0.81-0.92) NA NA 0.88 (0.82-0.93)
Overweight NA NA 0.91 (0.86-0.97) NA NA 0.87 (0.81-0.93)
Obese NA NA 1.08 (1.02-1.15) NA NA 0.91 (0.85-0.97)
Smoking status
Nonsmoker NA NA 1.00 (reference) NA NA 1.00 (reference)
Current/ex-smoker NA NA 1.47 (1.44-1.51) NA NA 1.36 (1.33-1.39)
Harmful alcohol use
No NA NA 1.00 (reference) NA NA 1.00 (reference)
Yes NA NA 2.09 (1.96-2.22) NA NA 1.99 (1.86-2.13)
High-dose glucocorticoids
No NA NA 1.00 (reference) NA NA 1.00 (reference)
Yes NA NA 1.84 (1.69-2.07) NA NA 1.94 (1.75-2.16)
NA, Not applicable/available.
All models were fitted to patients with complete data for all included variables. Sets without at least 1 exposed and 1 unexposed individual were excluded. HRs were estimated
from a Cox regression model with current age as the underlying timescale, stratified by matched set (sex, age, and general practice).
Minimally adjusted: N ¼ 1,980,710 (1,920,172 unique people) in the depression cohort and N ¼ 2,242,905 (2,171,784 unique people) in the anxiety cohort.
Adjusted for current calendar period and IMD at cohort entry (same participants as in minimally adjusted model).
Additionally adjusted for potential mediators: BMI (categorized as normal, 18.5-24.9 kg/m2; underweight, <18.5 kg/m2; overweight 25.0-29.9 kg/m2; and obese 30.0 kg/m2),
smoking status, and alcohol and high-dose corticosteroid use (20 mg/d prednisolone equivalent dose), as time-updated variables. N ¼ 1,371,005 individuals (1,322,284 unique
people) in the depression cohort and N ¼ 1,583,390 (1,583,390 unique people) in the anxiety cohort.
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TABLE E7. Absolute incidence rates, incidence rate differences (attributable risks), and population-attributable risks of depression and anxiety
Cohort
Estimated incidence rate
(per 100,00 PYAR)
in people with atopic eczema
HR comparing rate of depression/anxiety in
those with to those without
atopic eczema (99% CI)*
Inverse HR
(99% CI)†
Estimated incidence rate
(per 100,000 PYAR)
(99% CI) of depression/anxiety
in people without atopic eczema
Estimated incidence rate difference
(per 100,000 PYAR) (99% CI)
Estimated population-
attributable risk (%)
(99% CI)z
Depression 1331 1.14 (1.12-1.16) 0.88 (0.86-0.89) 1171 (1145-1185) 160 (146-186) 1.4 (1.2-1.6)
Anxiety 955 1.17 (1.14 to 1.19) 0.85 (0.84-0.88) 811 (802-840) 144 (115-153) 1.7 (1.4-1.9)
PYAR, Person-years at-risk.
*Adjusted for current calendar period (years: 1998-2001, 2002-06, 2007-11, and 2012-16) and quintiles of IMD at cohort entry.
†Comparing people without atopic eczema to people with atopic eczema.
zEstimated as P(HR  1)/(1 þ P(HR  1)) where P, the prevalence of atopic eczema, is assumed to be 10% and HR is the estimated HR.
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TABLE E8. Association between atopic eczema and anxiety/depression, by severity of atopic eczema vs no atopic eczema
Cohort/exposure No. Events/PYAR
Minimally adjusted
HR (99% CI)
Adjusted
HR (99% CI)
Additionally adjusted for
potential mediators HR (99% CI)
Depression*
Without atopic eczema 1,588,277 102,882/8,935,934 1.00 (reference) 1.00 (reference) 1.00 (reference)
With atopic eczema
Mild 287,944 19,116/1,436,377 1.10 (1.07-1.13) 1.10 (1.08-1.13) 1.07 (1.04-1.10)
Moderate 135,485 10,301/786,352 1.19 (1.15-1.23) 1.19 (1.15-1.23) 1.14 (1.10-1.18)
Severe 24,777 1,905/131,389 1.25 (1.16-1.35) 1.26 (1.17-1.37) 1.17 (1.08-1.28)
Anxiety†
Without atopic eczema 1,818,796 82,137/10,187,499 1.00 (reference) 1.00 (reference) 1.00 (reference)
With atopic eczema
Mild 310,205 15,093/1,543,672 1.14 (1.11-1.18) 1.14 (1.11-1.18) 1.11 (1.07-1.14)
Moderate 147,261 7,822/853,452 1.22 (1.17-1.26) 1.21 (1.17-1.26) 1.15 (1.11-1.20)
Severe 27,538 1,368/146,259 1.14 (1.05-1.25) 1.15 (1.05-1.25) 1.07 (0.97-1.18)
PYAR, Person-years at-risk.
All models were fitted to patients with complete data for all included variables. Sets without at least 1 exposed and 1 unexposed individual were excluded. HRs were estimated
from a Cox regression model with current age as the underlying timescale, stratified by matched set (sex, age, and general practice).
Minimally adjusted: N ¼ 1,980,710 (1,920,172 unique people) in the depression cohort and N ¼ 2,242,905 (2,171,784 unique people) in the anxiety cohort.
Adjusted for current calendar period and IMD at cohort entry (same participants as in minimally adjusted model).
Additionally adjusted for potential mediators: BMI (categorized as normal, 18.5-24.9 kg/m2; underweight, <18.5 kg/m2; overweight, 25.0-29.9 kg/m2; and obese, 30.0 kg/
m2), smoking status, and alcohol and high-dose corticosteroid use (20 mg/d prednisolone equivalent dose), as time-updated variables. N ¼ 1,371,005 individuals (1,322,284
unique people) in the depression cohort and N ¼ 1,583,390 (1,583,390 unique people) in the anxiety cohort.
*P values were <.0001 for linearity in all models, and 0.3810, 0.3832, and 0.6983 for departure from linearity in minimally adjusted, confounder-adjusted-, and additionally
adjusted for potential mediators models, respectively.
†P values were <.0001 for linearity in all models and <.0001 for departure from linearity in all models.
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TABLE E9. Secondary analysis, adjusted models: association between atopic eczema and depression/anxiety, stratified on sex, current
age (18-39, 40-59, 60þ y), and calendar period (1998-2001, 2002-2006, 2007-2011, 2012-2016)
Stratum/exposure
Depression Anxiety
Adjusted HR* (99% CI) No. Events/PYAR Adjusted HR* (99% CI)No. Events/PYAR
Sex† P < .0001 P ¼ .0003
Males
No atopic eczema 785,368 3,8219/4,512,990 1.00 (reference) 841,681 25,390/4,806,123 1.00 (reference)
Atopic eczema 181,315 10,891/1,086,295 1.19 (1.16-1.23) 187,784 7,196/1,122,110 1.22 (1.17-1.27)
Females
No atopic eczema 802,909 64,663/4,422,944 1.00 (reference) 977,115 56,747/5,381,375 1.000 (reference)
Atopic eczema 211,118 20,431/1,267,822 1.11 (1.08-1.13) 236,325 17,087/1,421,273 1.14 (1.11-1.17)
Current age† P < .0001 P ¼ .0052
18-39
No atopic eczema 828,072 48,992/3,265,435 1.00 (reference) 938,376 39,939/3,696,223 1.00 (reference)
Atopic eczema 195,455 14,175/834,206 1.10 (1.06-1.13) 210,072 11,476/901,165 1.14 (1.10-1.18)
40-59
No atopic eczema 485,291 26,208/2,553,247 1.00 (reference) 588,395 23,023/3,064,427 1.00 (reference)
Atopic eczema 123,489 8,624/675,274 1.22 (1.18-1.27) 138,864 7,031/756,141 1.21 (1.17-1.26)
60
No atopic eczema 530,344 27,682/3,117,252 1.00 (reference) 595,827 19,175/3,426,849 1.00 (reference)
Atopic eczema 139,919 8,523/844,638 1.12 (1.08-1.16) 149,256 5,776/886,077 1.15 (1.10-1.21)
Calendar period† P ¼ .3229 P ¼ .2871
1998-2001
No atopic eczema 476,794 17,175/1,143,231 1.00 (reference) 533,384 12,824/1,274,519 1.00 (reference)
Atopic eczema 113,944 4,888/279,596 1.14 (1.09-1.19) 121,449 3,499/297,984 1.15 (1.09-1.21)
2002-2006
No atopic eczema 762,671 28,735/2,341,702 1.00 (reference) 863,959 22,307/2,652,645 1.00 (reference)
Atopic eczema 187,774 8,525/595,943 1.15 (1.11-1.19) 201,836 6,298/642,215 1.15 (1.10-1.19)
2007-2011
No atopic eczema 1,000,682 32,533/3,137,512 1.00 (reference) 1,148,842 24,850/3,589,229 1.00 (reference)
Atopic eczema 256,158 9,916/836,225 1.12 (1.08-1.16) 277,719 7,441/905,501 1.18 (1.13-1.22)
2012-2016
No atopic eczema 923,647 24,439/2,313,488 1.00 (reference) 1,068,458 22,156/2,671,107 1.00 (reference)
Atopic eczema 248,593 7,993/642,355 1.15 (1.12-1.20) 270,531 7,045/697,684 1.19 (1.14-1.24)
PYAR, Person-years at-risk.
*All models were fitted to individuals with complete data for all included variables. Sets without at least 1 exposed and 1 unexposed individual were excluded. HRs were
estimated from a Cox regression model with current age as the underlying timescale, stratified by matched set (sex, age, and general practice), and adjusted for current calendar
period (years: 1998-2001, 2002-06, 2007-11, and 2012 16) and quintiles of IMD at cohort entry.
†P values for interaction and for stratum-specific effect were derived through likelihood-ratio tests.
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